Shared Pathogenesis of Infectious and Cardiovascular Diseases – Year 2005´s View
Authors:
P. Kuneš; J. Manďák; V. Lonský; V. Palička 1
Authors‘ workplace:
Kardiochirurgická klinika FN a LF UK, Hradec Králové
; Ústav klinické biochemie FN a LF UK, Hradec Králové
1
Published in:
Čas. Lék. čes. 2005; 144: 592-595
Category:
Review Article
Overview
Entry of microorganisms into the blood stream provokes a decline in the contractile function of the cardiac muscle. Lipopolysaccharide of Gram-negative bacteria sets off production of pro-inflammatory cytokines including bactericidal concentrations of nitric oxide which set up the first defence line against bacteremia. At the same time, however, the performance of the cardiovascular system is negatively affected. The immediate menace resides in the occurrence of septic shock, while chronic infectious diseases that are accompanied by low-grade inflammation have been suspected to take an active part in the initiation and progression of atherosclerosis. This hypothesis, as attractive as it may appear, has not yet been accepted unequivocally. The article offers an up-to-date review of the signalling cascades which permit activation by lipopolysaccharide of the target cells. The same holds true for cellular activation by non-infectious stimuli. An emerging paradigm seems plausible that the same biologic events which serve to combat acute infection might be in the long run involved in the pathogenesis of atherosclerosis.
Key words:
lipopolysaccharide, toll-like receptors, atherosclerosis.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistArticle was published in
Journal of Czech Physicians
Most read in this issue
- Latex Allergy – Report on Two Cases
- Differential Diagnosis of Peripheral Neuropathy
- Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma The First Experience in the Czech Republic
- Treatment of the Unresectable Non Small Cell Lung Carcinoma